#United States #Clinical Trials #Lexington #Curis #emavusertib

Curis Provides Business Update for Q2 2025

Curis, Inc. (NASDAQ: CRIS), a biotechnology company dedicated to advancing innovative cancer therapies, has shared significant progress in its business update for the second quarter of 2025. As the company focuses on its development of emavusertib (CA-4948), an oral IRAK4 inhibitor, the updates reveal promising advancements in clinical trials while also addressing the company’s financial standing.

Clinical Progress and Operational Highlights

During the recent conference call, CEO James Dentzer articulated the positive advancements in the TakeAim Lymphoma study, which is currently enrolling patients diagnosed with relapsed/refractory Primary Central Nervous System Lymphoma (PCNSL). This strategic enrollment is expected to hasten the process for accelerated approvals within the United States and the European Union. As part of their expanded treatment strategy, Curis is excited to announce a new clinical study combining emavusertib with a BTK inhibitor for Chronic Lymphocytic Leukemia (CLL), anticipated to provide transformative results for patients with significant unmet medical needs.

Emavusertib’s potential was highlighted at the American Society of Clinical Oncology (ASCO) meeting, where the genetic mutation profiles and pharmacokinetics of relapsed/refractory PCNSL patients were analyzed. Continuing the momentum, Curis remains steadfast in enrolling patients for the TakeAim Lymphoma study, which, following consultations with regulatory authorities, will now support patient registration.

In the realm of leukemia, Curis reported completing enrollment in the TakeAim Leukemia Phase 1/2 study, which evaluates emavusertib as a standalone treatment for patients with relapsed/refractory Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS). The company is also working on designing a pivotal head-to-head trial versus gilteritinib for AML. Collaboration with clinical trial investigators took place during ASCO and will continue at the European Hematology Association Congress, as there is a robust interest in combining therapies based on existing positive data trends.

Financial Snapshot

In terms of financial performance, for the second quarter of 2025, Curis reported a net loss of $8.6 million, translating to $0.68 per share, an improvement from the previous year’s loss of $11.8 million. Total revenues experienced a slight increase, registering at $2.7 million compared to $2.5 million in the same quarter last year. The revenue predominantly derives from royalties received from Genentech/Roche's sales of Erivedge®.

The company's research and development expenses saw a decline to $7.5 million from $10.3 million a year prior, mainly attributed to reduced clinical study costs and operational efficiencies. General and administrative expenses also dropped, emphasizing Curis's commitment to enhancing its operational efficiency amidst ongoing clinical trials and studies.

Looking at its balance sheet, Curis reported cash and cash equivalents amounting to $10.1 million as of June 30, 2025, complemented by an extension in its cash runway, which is now forecasted to last into the first quarter of 2026.

Future Outlook

With several presentations lined up at major upcoming healthcare conferences, including the H.C. Wainwright 27th Annual Global Investment Conference, the Curis team is gearing up to provide more insights into their ongoing research efforts and the promising data from ongoing clinical trials. As Curis continues its critical work in oncology treatments, its leadership remains optimistic about the future trajectory of emavusertib, both as a monotherapy and in combination treatments.

In conclusion, Curis, Inc.'s recent business updates reflect a strategic approach to their innovative therapies, bolstered by positive clinical developments and financial improvements. As they advance their studies and explore more avenues in oncology, the firm stands firm in its commitment to addressing unmet medical needs in cancer treatment, bringing hope to patients worldwide.

Conference Call Details

Curis's management conducted its latest conference call on August 5, 2025, revealing key updates and inviting interested parties to engage in discussions regarding their findings and forecasts.

About Curis Inc.

Curis, Inc. is dedicated to the research and development of innovative cancer therapies, with a specific focus on creating novel treatments that promise to drastically improve patient outcomes. Established collaborations and ongoing clinical trials play a pivotal role in Curis's mission to bring therapies to market that can alter the treatment landscape for patients suffering from severe forms of cancer.